Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian…
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line…